Lung Cancer Trial, Recruiting (NCT05623956)

Lung Cancer Trial, Recruiting NCT05623956 Sponsor: Aalborg University Hospital Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05623956 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are able to give written and signed consent to participate.
People who have been newly diagnosed with small cell lung cancer (SCLC), confirmed by laboratory analysis of tissue or cell samples.
People whose cancer can be measured on a CT scan.
People whose doctor determines they are suitable to receive standard chemotherapy using carboplatin and etoposide.

Who may not be able to join:

People who currently have another active cancer (confirmed by biopsy), apart from certain minor skin cancers or a very early-stage form of cervical cancer.
People who have previously received treatment for any cancer, other than certain minor skin cancers or a very early-stage form of cervical cancer.
People who are currently taking blood-thinning medications — though aspirin (acetylsalicylic acid) and clopidogrel are permitted.
People who are currently taking part in another clinical trial or receiving another experimental treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Weronika Szejniuk, MD, PhD, Aalborg University Hospital

Phone: 97606989

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05623956

Sponsor: Aalborg University Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: 97606989

More information: https://clinicaltrials.gov/study/NCT05623956

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are able to give written and signed consent to participate.
People who have been newly diagnosed with small cell lung cancer (SCLC), confirmed by laboratory analysis of tissue or cell samples.
People whose cancer can be measured on a CT scan.
People whose doctor determines they are suitable to receive standard chemotherapy using carboplatin and etoposide.

Who may not be able to join:

People who currently have another active cancer (confirmed by biopsy), apart from certain minor skin cancers or a very early-stage form of cervical cancer.
People who have previously received treatment for any cancer, other than certain minor skin cancers or a very early-stage form of cervical cancer.
People who are currently taking blood-thinning medications — though aspirin (acetylsalicylic acid) and clopidogrel are permitted.
People who are currently taking part in another clinical trial or receiving another experimental treatment.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Aalborg University Hospital

Registry

ClinicalTrials.gov

Start date

1 March 2023

Est. completion

1 December 2025

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Identification and validation of protein biomarkers

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov